Combining Tislelizumab and S-1 for Esophageal Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of combining Tegafur (S-1) with Tislelizumab in patients who have undergone radical resection for esophageal squamous cell carcinoma and have residual disease without lymph node involvement. The study aims to improve treatment outcomes for patients who have received neoadjuvant immunotherapy and chemotherapy. By focusing on patients with ypT1-4N0M0 staging, the trial seeks to explore a novel therapeutic approach in a population that has limited treatment options post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years old, gender is not limited;
2. Patients with esophageal squamous cell carcinoma with neoadjuvant immunotherapy combined with chemotherapy (radiotherapy was not planned during the study period);
3. Thoracic esophageal squamous cell carcinoma patients with residual pathologic primary site and lymph node positive (ypT1-4aN0M0) after surgery (8th UICC-TNM stage);
4. The operation was radical resection;
5. Physical status ECOG 0 \~ 1 score;
6. No local recurrence or distant metastasis was found in the examination before postoperative adjuvant treatment;
7. There were no contraindications of chemotherapy or immunotherapy in the evaluation of various organ functions;
8. Understand and sign the informed consent.

Exclusion Criteria:

1. Had malignant tumors other than esophageal cancer within 5 years prior to admission (cured localized tumors were not excluded, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, etc.); Prostate cancer patients who received hormone therapy and obtained DFS for more than 5 years were not excluded).
2. Prior history of interstitial lung disease, or pneumonia requiring steroid treatment when enrolled;
3. Receiving systemic steroid therapy (more than 10mg of prednisone per day or equivalent) or other immunosuppressant within 2 weeks prior to randomization;
4. People who have been severely allergic to chemotherapy drugs (fluorouracil) or any monoclonal antibody;
5. Patients with active autoimmune diseases;
6. Patients with active hepatitis
7. According to the judgment of the researcher, there are other circumstances that are not suitable for participation in this study.

Where it's running

• Army Medical Center of the People's Liberation Army
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Wei Guo
• Email: gyguowei@hotmail.com
• Phone: +86 13527323568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• Tislelizumab plus chemotherapy for advanced gastric, gastroesophageal, and esophageal squamous cancers in U.S. racial and ethnic minority patients

  This will test whether adding tislelizumab to standard chemotherapy helps U.S. racial and ethnic minority patients with HER2-negative, PD-L1-positive unresectable or metastatic gastric, gastroesophageal, or esophageal squamous cell cancer.

  Recruiting at 9 sites Phase 2 BeOne Medicines · Bullhead City, Arizona and 8 other locations · NCT07554521

• BL-B01D1 with Tislelizumab ± 5-FU as first-line treatment for unresectable, locally advanced recurrent, or metastatic esophageal squamous cell carcinoma

  A phase II/III trial tests BL-B01D1 with tislelizumab, with or without 5-FU, against standard platinum-based chemotherapy plus tislelizumab for adults with unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07554456

• Combining short-course radiotherapy with Raltitrexed and Tislelizumab for advanced esophageal cancer

  This study is testing a new treatment that combines short radiation therapy with two medications to see if it helps people with advanced esophageal cancer that has come back or gotten worse.

  Recruiting Anhui Provincial Hospital · Hefei · NCT06408584

• Combining Tislelizumab with Chemotherapy for Esophageal Cancer Treatment

  This study is testing if combining a new immune therapy called tislelizumab with chemotherapy can help people with esophageal cancer live longer and stay cancer-free after surgery.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06056336

• Combining chemotherapy with Tislelizumab for esophageal cancer after surgery

  This study is testing if combining an immunotherapy drug called Tislelizumab with chemotherapy can help people with esophageal cancer live longer after surgery.

  Recruiting Phase 1 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong · NCT05984342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.